Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IGXT ready to GOOOOOOOOOOOOOOOO!
Charts are beautiful - just need some volume and this thing is a rocket! C'mon
Everything is pathetic right now... thought you were selling out?
Better to beat projections than to show failure - they're looking for long term rather than an overnight pump and dump
WOW... Everyone see that 205k buy at the end of the day and the 122k at the beginning of the day? Someone wants in... Allow them to continue buying!
I am quite pleased with the move to OTCQX and I believe we don't have much longer before this thing needs a kevlar vest because it'll be ballistic. The few buys coming through today were decent sized buys and once this breaches .54, I have a feeling we won't be looking back! A listtle more awareness of this and we have it made
Bounced off the 50 day MA and also still in an uptrend! Won't be long and they'll have to let this go
What I saw the past couple days was a very large buy, followed by getting brought down on smaller sells. Someone buying 99.5k at .69 has to be fairly confident in their purchase, only to see it drop to .64 on smaller stuff! Crazy, but shorts are still temporarily in control for the moment, need the co to come out with some juicy stuff!
Could it be possible in the contract they aren't allowed to purchase IGXT stock? Maybe to keep the companies separate, yet do biz together
IGXT moved up to the OTCQX Market
IntelGenx Upgrades to OTCQX(R), the Highest Tier of the OTC Market, on June 14, 2012
Date : 06/14/2012 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Intelgenx Technologs (IGXT)
Quote : 0.47 -0.02 (-4.08%) @ 10:00AM
IntelGenx Upgrades to OTCQX(R), the Highest Tier of the OTC Market, on June 14, 2012
Intelgenx Technologs (OTCBB:IGXT)
Intraday Stock Chart
Today : Thursday 14 June 2012
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced that its common stock will begin trading on the prestigious OTCQX® U.S. trading platform with effect from June 14, 2012. The OTCQX® is the highest tier of the OTC market and is exclusively for companies that meet the highest financial standards and undergo a qualitative review. IntelGenx' trading symbol, IGXT, will remain the same. In addition, the Company's common shares will continue to trade on the TSX Venture Exchange under the symbol IGX.
"I am extremely pleased with our upgrade to the OTCQX®" stated Dr. Horst Zerbe, President and CEO of IntelGenx. "Trading on the OTCQX® marketplace is an important step for IntelGenx' continued growth and will provide increased visibility and access to U.S. investors'.
About OTCQX®:
The OTCQX marketplace is the premier tier of the U.S. over-the-counter market. Investor-focused companies use the quality-controlled OTCQX marketplace to offer investors transparent trading, superior information and easy access through their regulated U.S. broker-dealers.
About IntelGenx:
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2011, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Each of the TSX Venture Exchange and OTC Markets Group, Inc. has neither approved nor disapproved the contents of this press release.
CONTACT: Dr. Horst G. Zerbe,
President and CEO
IntelGenx Technologies Corp.
T: +1 514-331-7440 (ext. 201)
F: +1 514-331-0436
horst@intelgenx.com
www.intelgenx.com
OTCQX is top tier of OTC market showing full transparency
Some of the OTCQX companies have market caps in the BILLIONS such as some you may know of or have heard of
adidas AG ADDYY OTCQX International Premier Deutsche Bank Sporting and athletic goods, misc Germany Nov 2, 2007 15,042,630,400
Deutsche Telekom AG DTEGY OTCQX International Premier Deutsche Bank Telephone communication, except radio Germany Jun 21, 2010 $43,731,748,280
Experian plc EXPGY OTCQX International Premier BNY Mellon Credit reporting services Jersey Nov 19, 2010 $14,559,812,820
Gazprom Neft GZPFY OTCQX International Premier BNY Mellon Oil and gas field services, misc Russian Federation Aug 3, 2009 $20,435,001,444
Infineon Technologies AG IFNNY OTCQX International Premier Deutsche Bank Semiconductors and related devices Germany Apr 24, 2009 $8,335,340,554
Roche Holding Ltd RHHBY OTCQX International Premier J.P. Morgan Diagnostic substances Switzerland Nov 19, 2007 115,726,177,360
Volkswagen AG VLKPY OTCQX International Premier J.P. Morgan Motor vehicles and car bodies Germany May 7, 2012 50,851,212,570
Volkswagen AG VLKAY OTCQX International Premier J.P. Morgan Motor vehicles and car bodies Germany May 7, 2012 67,551,772,794
IntelGenx Technologies Corp. IGXT OTCQX U.S. Dorsey & Whitney LLP Pharmaceutical preparations United States Jun 14, 2012 $24,314,711
I myself am glad to see the company taking steps to show transparency and on the OTCQX Exchange, they have some great company!
On this PAGE you can download the full list of OTCQX companies (ONLY ABOUT 380 companies have achieved this tier) - some with market caps up to $115 BILLION DOLLARS
Very nice news...
http://www.otcqx.com/qx/otcqx/overview
Make Engaging Investors Your Priority
The OTCQX marketplace is the premier tier of the U.S. Over-the-Counter (OTC) market, providing investors with an objective measure to distinguish the best OTC-traded companies.
Investor-focused companies use the quality-controlled OTCQX platform to offer investors transparent trading, superior information, and easy access through their regulated U.S. broker-dealers. The innovative OTCQX platform offers companies and their investors a level of marketplace services formerly available only on a U.S. exchange.
Investors prefer the quality controlled admission process on OTCQX which identifies the segment of OTC-traded companies focused on valuation and transparency.
Who Should Join OTCQX
Many U.S. companies join OTCQX as the final step toward a NASDAQ or NYSE listing. Others enjoy the efficient compliance-driven and cost-effective model it offers their investors outside of a traditional exchange listing. For companies moving off a U.S. exchange, OTCQX is the ideal home, providing most of the services the company and their investors have come to expect from a listed market.
Why Investors Prefer OTCQX
OTCQX separates out the credible companies from the large number of economically distressed and questionable companies that trade OTC. Companies that join OTCQX demonstrate their commitment to providing superior information to investors and maintaining the highest quality standards.
OTCQX is fully electronic and gives investors access through all major online and full-service brokerage firms in the U.S., including Schwab, E*TRADE, Scottrade, TD Ameritrade, and Fidelity. Trades are settled and cleared in the U.S. similar to any NASDAQ or NYSE stock and trade reports are disseminated through Yahoo, Bloomberg, Reuters, and most other financial data providers.
In addition, investors can view Real-Time Level 2 Quotes for all OTCQX companies for free on otcqx.com providing access to detailed market data, including market depth.
Services to Issuers
OTCQX provides services to companies which enable them to communicate with and engage their investors, while providing them with transparent trading and easy access to company information. OTCQX is the only highly visible electronic trading venue in the U.S. that does not require SEC registration.
OTCQX includes:
OTC Disclosure and News Service allows Investor Relations officers to communicate with their U.S. investor base and access OTC Markets Group’s OTC Market Intelligence product. OTCIQ provides both real-time and historical quote and trade data and a weekly Market Report summary of trading activity, which can be conveniently re-distributed to directors, company management, and shareholders
Access to the OTCQX Market Center at OTC Markets Group’s headquarters in New York City to conduct investor meetings and conferences
Blue Sky Monitoring Service allows brokers to discuss and recommend your company's stock to their investing clients
Established, superior electronic quotation and trading platform with connectivity to all major U.S. broker-dealers, easily accessible for both institutional and retail investors
Market Services Specialist that is available to answer your calls and assist you with any questions you may have on your security's trading performance and market maker information
Detailed quote and trade information can also be displayed on a company’s websites, making this information more visible for your U.S. investors
Links & Documents
OTCQX Application
OTCQX Agreement
OTC Company PR Guidance
Not lookin extremely pretty... Already down to .71 pre-split
Biodel Announces Effectiveness of Reverse Stock Split
Biodel Inc. (MM) (NASDAQ:BIOD)
Intraday Stock Chart
Today : Tuesday 12 June 2012
Biodel Inc. (Nasdaq:BIOD) today announced that its Board of Directors has approved a reverse split of its common stock (the "Reverse Stock Split") at a ratio of one-for-four. The Company's common stock will begin trading on a split-adjusted basis when the NASDAQ Capital Market opens on June 12, 2012.
At Biodel's annual meeting of stockholders held on March 8, 2012, the stockholders granted the Board of Directors the authority to approve and proceed with the Reverse Stock Split, in the Board's discretion. The purpose of Reverse Stock Split is to raise the per share trading price of Biodel's common stock to regain compliance with the $1.00 per share minimum bid price requirement for continued listing of Biodel's common stock on The NASDAQ Capital Market.
The Reverse Stock Split became effective at 5:00 p.m. Eastern Daylight Time on June 11, 2012. The Reverse Stock Split will be effective for trading purposes at the opening of the market on June 12, 2012. Due to the Reverse Stock Split, Biodel's common stock will now trade under a new CUSIP number, 09064M 204. The common stock will continue to trade under the symbol BIOD.
As a result of the Reverse Stock Split, each outstanding share of Biodel common stock was automatically changed into one-quarter of a share of common stock. Also, as previously announced, the number of authorized shares of Biodel common stock was fixed on a post-split basis at 25,000,000 in connection with the Reverse Stock Split.
No fractional shares will be issued as a result of the Reverse Stock Split. Holders of common stock who would otherwise receive a fractional share of common stock pursuant to the Reverse Stock Split will receive cash in lieu of the fractional share.
Continental Stock Transfer & Trust Company is the exchange agent for the Reverse Stock Split and will distribute a letter of transmittal to record holders with instructions for the surrender and exchange of old stock certificates and for receiving cash in lieu of fractional shares, if applicable. Stockholders who hold their shares in "street name" will be contacted by their banks or brokers with any instructions.
For more information on the Reverse Stock Split, please refer to Biodel's proxy materials for its most recently held annual meeting of stockholders, which can be accessed through Biodel's website at http://investor.biodel.com/secfiling.cfm?filingID=1145443-12-54.
About Biodel
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding Biodel, please visit the company's website at www.biodel.com.
Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with Type 1 and Type 2 diabetes; our ability advance a proprietary insulin formulation into a Phase 2 clinical trial in a timely manner; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject®), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended March 31, 2012. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
BIOD-G
I see reverse split as having possibly both positive and negative impacts here.
Positives being higher share price which will allow funds to purchase if desired (most can't purchase under $1, and the "look/desire" of THQ not being a penny stock
Negatives being the "stigma" of having a reverse split, less shares out there for the shorts to continue their shorting like crazy, and no reasonings given for choosing reverse split over an extension and/or company buyback of xx amount of shares at these low prices to get us back over $1.
BURN SHORTY BURN!!!!!!!!!!!
Even more news...
http://fyxnews.com/smw/28151/Seven-NASDAQ-Stocks-under-Four-Bucks-to-Watch-for-Thursday-
Seven NASDAQ Stocks under Four Bucks to Watch for Thursday
5/30/2012 10:02:09 PM
--------------------------------------------------------------------------------
Hoku Corporation (NASDAQ:HOKU) traded as high as $.15 during Wednesday’s trading session and last traded at the high for a gain of 80.07% from Tuesday’s close… HOKU shares have traded as high as $2.05 over the past 52 weeks, which is 92.68% off that high at last traded stock price. Get my next ALERT 100% FREE
Hoku Corporation is a solar energy products and services company. The Company focused on the design and development of fuel cell technologies, including Hoku membrane electrode assemblies (MEAs) and Hoku Membranes. The Company has two business units: Hoku Materials and Hoku Solar.
Vision-Sciences, Inc. (NASDAQ:VSCI) traded as high as $1.57 during Wednesday’s trading session and last traded at the high for a gain of 20.77% from Tuesday’s close… VSCI shares have traded as high as $2.7299 over the past 52 weeks, which is 42.49% off that high at last traded stock price.
Vision-Sciences, Inc. designs, develops, manufactures, and markets products for endoscopy - the science of using an instrument, known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye.
Rand Capital Corporation (NASDAQ:RAND) traded as high as $3.29 during Wednesday’s trading session and last traded at $3.25 for a gain of 16.49% from Tuesday’s close… RAND shares have traded as high as $4.19 over the past 52 weeks, which is 22.43% off that high at last traded stock price.
Rand Capital Corporation (Rand) operates as a venture capital company. The Company’s principal business is to make venture capital investments in small to medium-sized companies that are engaged in the exploitation of products or services in New York and its surrounding states.
Zogenix, Inc. (NASDAQ:ZGNX) traded as high as $1.887 during Wednesday’s trading session and last traded at $1.84 for a gain of 15.72% from Tuesday’s close… ZGNX shares have traded as high as $5.11 over the past 52 weeks, which is 63.99% off that high at last traded stock price. Get my next ALERT 100% FREE
Zogenix, Inc. is a specialty pharmaceutical company with two product candidates in late-stage development for the treatment of central nervous system (CNS) disorders and pain. The Company’s lead product candidate, sumatriptan DosePro, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine.
Dynasil Corporation of America (NASDAQ:DYSL) traded as high as $1.90 during Wednesday’s trading session and last traded at $1.64 for a gain of 12.33% from Tuesday’s close… DYSL shares have traded as high as $3.71 over the past 52 weeks, which is 55.8% off that high at last traded stock price.
Dynasil Corporation of America is a provider of technology, products, services and solutions. The Company develops and manufactures specialized sensors, precision instruments and optical products, including nuclear detectors and medical probes, for the medical, industrial and homeland security/defense markets.
THQ Inc. (NASDAQ:THQI) traded as high as $.69 during Wednesday’s trading session and last traded at $.6499 for a gain of 12.05% from Tuesday’s close… THQI shares have traded as high as $4.24 over the past 52 weeks, which is 84.67% off that high at last traded stock price.
THQ Inc. is a worldwide developer and publisher of interactive entertainment software for all game systems, including home video game consoles, such as the Microsoft Xbox 360 (Xbox 360), Nintendo Wii (Wii), Sony PlayStation 3 (PS3) and Sony PlayStation 2 (PS2); handheld platforms, such as the Nintendo DS and DSi (collectively referred to as DS), and Sony PlayStation Portable (PSP); wireless devices, including the iPhone, iTouch and iPad, and personal computers (PCs), including games played online.
Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) traded as high as $3.25 during Wednesday’s trading session and last traded at $3.16 for a gain of 11.66% from Tuesday’s close… AMPE shares have traded as high as $9.27 over the past 52 weeks, which is 65.91% off that high at last traded stock price. Get my next ALERT 100% FREE
Ampio Pharmaceuticals, Inc., is a development stage biopharmaceutical company. The Company is engaged in discovering and developing pharmaceutical drugs and diagnostic products to identify, treat, and prevent a range of human diseases including metabolic disorders, eye disease, kidney disease, acute and chronic inflammation, and male sexual dysfunction.
Read more: http://fyxnews.com/smw/28151/Seven-NASDAQ-Stocks-under-Four-Bucks-to-Watch-for-Thursday-#ixzz1wSFVosK0
Shorts would be reversed to, to same ratio! If someone shorted 1 million shares and they reversed at 5:1 leaving 13 mil os, they would only be liable for 100,000 shares rather than million! They change at same ratio...
I don't see a big squeeze anytime soon! If that were the case we wouldn't have 20% of the shares short right now, I could see it causing some of the longs to jump out and further reason for the shorts to continue!
Pretty sad when the company has more in cash at its worst financial moment than market cap of all shares, including 20% short shares!
Now if the company were to reduce the A/S in proportion to the r/s may be a little different story, but telling averting they could own 1/10 the shares they currently do and get diluted up to 240+ million shares? How is that going to create demand?
The company may not reverse, but have an escape route just in case the pls doesn't rise, but until end of year I see no upside without a buyout offer or massive insider buying -in both of which could keep the reverse split from even needed to be debated
Shorts don't have to cover with it without a reverse unless they have a reason to (such as like you said institutions buying in since the price is acceptable). There should be a 30 day limit on any short shares at most rather than allowing someone to short for eternity and never have to cover!
. Duplicate
Pre14a filing to ask shareholders to allow a reverse split. Either a 3:1, 5:1, or 10:1 reverse at the companies discretion!
Don't think it would lose value after the reverse, but would like to see the company provide a reason to buy and also get an extension rather than reverse split! Over 25% of the shares short in a company and nothing the sec can do about that? Effectively, if you have enough money you can kill any company/stock price which is BS and only works for the mega rich!
Since no one holds paper certs anymore, it's very easy for them to short into eternity!
Delivery at some later date is nothing but a button on the keyboard, if they ever have to deliver!
Time for the BEAR RAID to create fear! NO? What the hell buy is that at .69? BIG FISHES
Yes... Nice trading
1 million shares and up 9% before earnings! LOOKIN GOOD
Maybe they're going to have a lot of news coming out during the runup next couple days until financials!
Would make alot of sense to already have the pps heading NORTH, then blow away everyone with financials and forecast!
Nexuiz PC Launches Today
Thq Inc. (MM) (NASDAQ:THQI)
Intraday Stock Chart
Today : Thursday 10 May 2012
THQ Inc. (NASDAQ: THQI) and Machinima today announced the immediate launch of Nexuiz PC for $9.99 on Steam and other digital download sites.
Nexuiz is the CryENGINE® 3 powered Arena FPS from Illfonic.
“Nexuiz is the competitive shooter,” said Kedhrin Gonzalez, Creative Director at Illfonic. “We’ve done a lot of community outreach, listened to our fans and included their ideas in Nexuiz. It is faster, more intense and more fun than ever. PC gamers, especially competitive gamers, want speed, high-quality graphics and non-stop action.”
The PC version of Nexuiz will include a number of enhancements and changes over the console version including:
• Dedicated Server Support and Server Browser
• Enhanced, CryENGINE 3 powered graphics with DX11 support
• Advanced custom controls, new HUD and a 20% increase to player speed for ultimate twitch-shooter experience
More details can be found on the Nexuiz community forums at Forums.Nexuiz.com
Nexuiz for PC is now available from Steam at Store.Steampowered.com/app/96800.
About Nexuiz for PC
For centuries the Kavussari and the Forsellians have waged war. They have a fragile truce but due to their seething disgust of each other they still pit their warriors against each other in arenas rather than on the fields of war.
Those episodes of lethal combat are now broadcast throughout the galaxy, as entertainment… a spectacle known as… The Nexuiz Competition: An arena based first person shooter where you can alter the rules of the match and laws of physics while you dominate opponents in ever-changing hostile environments bleeding with hatred.
• Arena FPS is back – inspired by the giants of the Arena FPS genre, Nexuiz reinvents twitch gaming for PC
• Rebuilt for the PC – dedicated server support, DX11 graphics and game speed and controls tuned for the discerning PC player makes this the best version of Nexuiz yet
• Over 100 ‘Dynamic Mutators’ serve as game-changing power-ups – Jetpacks, Uber-Nuke, Low Gravity, Big Head Mode and many more...
• 9 deadly arenas – powered by CryENGINE 3, Nexuiz sets a new graphical benchmark for a digital-only release
• Designed for competitive play - a superbly balanced weapon set, classic game modes, and extensive stat tracking, Medals and Leaderboard support
• Play solo or online – hone your skills against bots, then wage war online against the best in 4v4 multiplayer matches
• Just $9.99 – Nexuiz offers hours of gameplay and unprecedented production values for a $10 title
For more information on Nexuiz, ‘Like’ us at http://Facebook.com/NexuizShooter, follow us at http://Twitter.com/NexuizShooter or visit the official website at http://Nexuiz.com.
About THQ
THQ Inc. (NASDAQ: THQI) is a leading worldwide developer and publisher of interactive entertainment software. The company develops its products for all popular game systems, personal computers and wireless devices. Headquartered in Los Angeles County, California, THQ sells product through its global network of offices located throughout North America, Europe and Asia Pacific. More information about THQ and its products may be found at www.thq.com. THQ and the THQ logo are trademarks and/or registered trademarks of THQ Inc.
All other trademarks are the property of their respective owners.
The statements contained in this press release that are not historical facts may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations, estimates and projections about the business of THQ Inc. and its subsidiaries (collectively referred to as “THQ”), including, but not limited to, expectations and projections related to the release of Nexuiz, and are based upon management’s current beliefs and certain assumptions made by management. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, business, competitive, economic, legal, political and technological factors affecting our industry, operations, markets, products or pricing. Readers should carefully review the risk factors and the information that could materially affect THQ’s financial results, described in other documents that THQ files from time to time with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal period ended March 31, 2011, and subsequent Quarterly Reports on Form 10-Q, and particularly the discussion of trends and risk factors set forth therein. Unless otherwise required by law, THQ disclaims any obligation to update its view on any such risks or uncertainties or to revise or publicly release.
About Machinima
Machinima is the dominant video entertainment network for serious gamers around the world. The number one entertainment channel on YouTube, Machinima serves over 1.6 billion video views a month, and reaches over 166 million gamers monthly. Machinima’s global content network features official publisher content, gameplay videos and original content, including over 20 original weekly shows, all aimed at the coveted 18 – 34 year old male demographic. Machinima is fast-becoming a global phenomenon with an ability to capture a cultural sensibility and awareness among a next generation of entertainment consumers and marketers alike. The company is backed by MK Capital and Redpoint Ventures, and is headquartered in Los Angeles, California.
For more information, please visit www.machinima.com
About IllFonic
Illfonic is an indie video game development studio committed to delivering AAA games digitally to consoles and PC. Launched in 2007, IllFonic utilizes many avenues in pop culture to cross brand its products in film, television, sports, music and clothing. With offices in Los Angeles and Denver, the company has built a team of artists, developers, producers and musicians who believe that providing fun game-play means conveying the highest level of visual and musical awe along with an immersive environment.
Xbox, Xbox 360, and Xbox LIVE are either registered trademarks or trademarks of the Microsoft group of companies.
All other trademarks are the property of their respective owners.
Good eye... Edgemont is also listed on that page with diff drug so apparently Edgemont is getting around!
They do not have to immediately file a form 4.. I believe the shares could have been purchased over a couple days and within xx amount of time the form 4 needs to be filed!
Want everyone to be careful, some schmucks on yahoo are posting false info (reverse splits & changing symbols)
At least we know with this BS the price is going UP - otherwise they wouldn't be doing it!
I believe things will go very well later on... It's just getting to that point :(
Good results shown - I wasn't lucky/smart enough to sell out last year so still holding a lot higher price as in around $1.5 avg
April 15, 2012
Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
Conference Call Scheduled for Monday, April 16, at 8:30 AM EDT
DANBURY, Conn., April 15, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting formulations of recombinant human insulin (RHI).
•BIOD-123 and BIOD-125 achieved the Company's target pharmacokinetic, pharmacodynamic and toleration profiles in a Phase 1 clinical trial; BIOD-123 favored as lead product candidate to advance to Phase 2
•Projecting initiation of a Phase 2 clinical trial of BIOD-123 in the third calendar quarter of 2012
•Continuing development of ultra-rapid-acting insulin analog-based formulations with selection of candidates and initiation of a Phase 1 clinical trial projected in the second half of calendar year 2012
•Liquid glucagon formulation for use as a rescue treatment for patients experiencing severe hypoglycemia projected for NDA submission in the fourth calendar quarter of 2013 or first calendar quarter of 2014
The Phase 1 clinical trial evaluated the pharmacokinetic, pharmacodynamic and injection site toleration profiles of BIOD-123 and BIOD-125 relative to Humalog®, a rapid-acting insulin analog. The objective of the trial was to identify an RHI-based formulation with pharmacokinetic and pharmacodynamic profiles similar to the Company's previous Linjeta™ formulation used in Phase 3 clinical trials, but with improved injection site toleration characteristics. The Phase 1 clinical trial was a single-center, randomized, double-blind, three-period crossover trial in 12 patients with Type 1 diabetes. Each study drug was administered subcutaneously on separate days with a washout period between injections.
Pharmacokinetic measurements were made using separate assays to quantify the active ingredients in the study drugs — RHI in the case of BIOD-123 and BIOD-125 and insulin lispro in the case of Humalog®. The clinical trial was powered to measure differences in time to half maximal insulin concentrations. Pharmacodynamic measurements were assessed using the euglycemic clamp method. Local injection site discomfort was measured with a 100 mm visual analog scale (VAS) and patient questionnaires.
In the Phase 1 clinical trial, absorption rates of BIOD-123 and BIOD-125 were significantly faster than that of Humalog® as indicated by 64% and 54% reductions, respectively, in mean times to half maximal insulin concentrations (p < 0.001 for both BIOD-123 and BIOD-125 compared to Humalog®). In a previous clinical trial, the Linjeta™ formulation demonstrated a 61% reduction compared to Humalog®. Peak metabolic effects were not significantly different between the three study drugs.
All three were well tolerated, with injection site tolerability generally perceived by patients to be similar to that of their usual mealtime injections used at home. As measured on a 100 mm visual analog scale in which 100 mm is defined as the worst possible injection discomfort, local toleration was not significantly different for BIOD-123 compared to Humalog® (BIOD-123 mean VAS 3.6 +/- 2.1 mm, Humalog® 1.8 +/- 1.1 mm, p=NS). The VAS score for BIOD-125 was slightly higher as compared to Humalog® (mean VAS 6.8 +/- 2.9 mm, p < 0.05). However, this score was markedly improved relative to the Linjeta™ formulation, which had a mean VAS of 22.0 +/- 2.8 mm in a previous study.
Dr. Alan Krasner, Biodel's chief medical officer, stated: "Biodel's previous Linjeta™ formulation demonstrated a desirable ultra-rapid absorption profile, but had challenges with respect to local injection site toleration. The goal of our subsequent formulation development has been to maintain the ultra-rapid absorption profile of Linjeta™, while improving injection site toleration. These recent data suggest that our latest formulations have achieved this goal, and we feel that further clinical development is warranted."
Dr. Errol De Souza, Biodel's president and chief executive officer, stated: "The findings from these studies are very encouraging and will enable us to advance an ultra-rapid-acting RHI-based formulation into a Phase 2 clinical trial as early as next quarter. In parallel, we will continue our development of ultra-rapid-acting insulin analog-based formulations, with the goal of advancing product candidates into a Phase 1 clinical trial later in 2012. We expect our ultra-rapid-acting insulin program, along with our liquid glucagon rescue program that is targeted for NDA filing by the end of 2013 or early 2014, to generate multiple meaningful milestones in the short-term."
Phase 1 Study in Patients with Type 1 Diabetes (n=12)
Pharmacokinetic Profiles of BIOD-123, BIOD-125 and Humalog®
Treatment
Metrics
Early 1/2 Tmax
(minutes)
Tmax
(minutes)
Late 1/2 Tmax
(minutes)
Humalog®
27.0 +/- 2.7
(25.9)
65.0 +/- 7.0
(67.5)
151 +/- 11
(150)
BIOD-123
9.8 +/- 1.1*
(9.6)
46.4 +/- 14.9
(25.0)
206 +/- 35
(170)
BIOD-125
12.4 +/- 2.0*
(9.4)
60.8 +/- 15.2
(30.0)
179 +/- 41
(140)
-- Data represent the Mean +/- SEM; Median Values are presented in parentheses.
* p < 0.001 vs. Humalog®
Injection Site Toleration Profiles of BIOD-123, BIOD-125 and Humalog®
Treatment
Metrics
Tolerability
(VAS 0 — 100mm)
Absolute Severity
Score
Relative Severity Score
Humalog®
1.8 +/- 1.1
0.17 +/- 0.11
2.92 +/- 0.08
BIOD-123
3.6 +/- 2.1
0.36 +/- 0.15
2.91 +/- 0.25
BIOD-125
6.8 +/- 2.9*
0.50 +/- 0.19
3.08 +/- 0.26
-- 100 mm Visual Analog Scale: 0=no discomfort, 100=worst possible discomfort
-- Absolute Severity Scale: 0=None, 1=Mild, 2=Moderate, 3=Severe
-- Relative Severity (compared to usual meal-time injections): 1=Much less, 2=Less, 3=Equal, 4=Increased, 5=Greatly increased
* p < 0.05 vs. Humalog®
Biodel's senior management will host a conference call to discuss the results and provide an update on the Company's progress.
April 16, 2012 schedule:
8:15 am EDT:
Conference call participants should dial:
+1 ( 877 ) 303 — 8028 (United States) or
+1 ( 760 ) 536 — 5167 (International)
8:30 am EDT:
Conference call begins
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel's website at www.biodel.com. The audio webcast will be archived and available for replay through the website.
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic profiles. For further information regarding Biodel, please visit the company's website at www.biodel.com.
Safe-Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with Type 1 and Type 2 diabetes; our ability advance a proprietary insulin formulation into a Phase 2 clinical trial in a timely manner; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject®), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended December 31, 2011. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
BIOD-G
Contact: Seth D. Lewis, +1-646-378-2952
SOURCE Biodel Inc.
News Provided by Acquire Media
Eh, would be a totally different market if they actually were forced to cover short shares sold in a reasonable amount of time (say 10 biz days) but letting them sell short for unlimited time frames??? Every stock goes down at some point doesn't it so if you have the $$$ just short sell anything and you'll make money on 80% of what you sold short! Enough short sellers could bring down apple/google!!!
Sucks to be the ones without the large cash at their hands!
Once good news hits they won't be able to keep it down anymore... :)
Well, the nice bid at .72 should keep us from going below that anytime soon... Would take 10% of todays volume to break through it
I see a close of .74 today!
Most of the market has the "I WANT IT NOW" sentiment rather than wait for the good times to come. They're thinking why should my money sit in IGXT for 6 months to a year to make 100% gain when I can jump in/out of different stocks for 500+ % gains, then when IGXT starts taking off I can jump in for a 50% gain...
The whole market is messed up - maybe IGXT will deliver us some blockbuster news and they won't be able to get in for their 50% gain and we'll make 300% on a safe stock play :)
Shorts trying to keep control until they're covered.. Any buying pressure we'll be right back up!
Should be over 2 million volume by 10:00 at this rate!
I say we close at .82 today, any other guesses?
Nice story... He brings up IGXT in the article (not too much, but about CPI-300)
Not sure if there is a way to copy/paste out of that online paper, I'd say it's just as easy for anyone to go directly to the paper
Link to Article/Newspaper
That should open the one you need, then page 5 on right side, 6 in middle!
THQI - undervalued play
68 mil OS with 13 mil short
174 mil revenue projected for this quarter
less loss than estimated (a large part due to one time costs with restructuring)
Games selling well
Going back to creating the more lucrative games
buyout rumors due to being so undervalued on multiple sites
Chart looks great - set up for a run to at least $1.5 and much higher if the shorts don't get out quick! Awesome volume coming in...
THQI - the short squeeze is coming... close at high of day, revenues to be better than projected! 13 mil short with $68 mil OS. More cash on hand than market cap!
THQI going... Should be a nice multi-day run!
We get above .67 and there's no telling where we'll close :)
Agreed.. I wasn't here to watch, either someone bought up those shares or they pulled the sale! Off we GO